Premium
Immunohistochemical expression of HER1, HER3, and HER4 in HER2‐positive breast cancer patients treated with trastuzumab‐containing neoadjuvant chemotherapy
Author(s) -
Yonemori Kan,
Tsuta Koji,
Shimizu Chikako,
Hatanaka Yutaka,
Hirakawa Akihiro,
Ono Makiko,
Kouno Tsutomu,
Katsumata Noriyuki,
Ando Masashi,
Tamura Kenji,
Hasegawa Tadashi,
Kinoshita Takayuki,
Fujiwara Yasuhiro
Publication year - 2010
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21486
Subject(s) - trastuzumab , medicine , immunohistochemistry , breast cancer , chemotherapy , oncology , cancer , biomarker , adjuvant , pathology , biology , biochemistry
Background and Objectives The aim of the present study was to examine the association between the expression of human epidermal receptor (HER) 1, HER3, and HER4 and pathologic complete response (pCR) in HER2‐positive patients treated with trastuzumab‐containing neo‐adjuvant chemotherapy. Methods Immunohistochemical analyses of HER1, HER3, and HER4 were performed using tumor specimens obtained from patients treated with trastuzumab‐containing neoadjuvant chemotherapy. The staining intensity of each biomarker was evaluated, and the correlations between the immunohistochemical profiles and pCR were examined. Results The present study included 44 patients with HER2‐positive breast cancer treated with trastuzumab‐containing neo‐adjuvant chemotherapy. Seventeen patients achieved a pCR. The expressions of HER1, HER3, and HER4 were observed in 18.2%, 27.3%, and 18.2% of the specimens, respectively. A marginally significant negative correlation between the expression of HER1 and pCR was observed, irrespective of the expression of HER3 and HER4, whereas the expressions of HER3 and HER4 were not significantly correlated with pCR. Conclusion The expression of HER1 might be an independently negative predictor of pCR in HER2‐positive breast cancer patients treated with trastuzumab‐containing neoadjuvant chemotherapy. J. Surg. Oncol. 2010; 101:222–227. © 2010 Wiley‐Liss, Inc.